Your browser doesn't support javascript.
loading
Apoptins: selective anticancer agents.
Rollano Peñaloza, Oscar M; Lewandowska, Magdalena; Stetefeld, Joerg; Ossysek, Karolina; Madej, Mariusz; Bereta, Joanna; Sobczak, Mateusz; Shojaei, Shahla; Ghavami, Saeid; Los, Marek J.
Afiliação
  • Rollano Peñaloza OM; Department Clinical & Experimental Medicine, Division of Cell Biology, and Integrative Regenerative Medical Center, Linköping University, Linköping, Sweden; Instituto de Biologia Molecular y Biotecnologia, La Paz, Bolivia.
  • Lewandowska M; Department of Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Stetefeld J; Department of Chemistry, University of Manitoba, Winnipeg, Canada.
  • Ossysek K; Department of Cell Biochemistry, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
  • Madej M; Department of Cell Biochemistry, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
  • Bereta J; Department of Cell Biochemistry, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
  • Sobczak M; Department of Medical Biotechnology, Faculty of Biochemistry Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland.
  • Shojaei S; Department of Biochemistry, Recombinant Protein Laboratory, Medical School, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Ghavami S; Department of Human Anatomy & Cell Science, College of Medicine, Faculty of Health Sciences, and Manitoba Institute of Child Health, University of Manitoba, Winnipeg, Canada; Health Policy Research Centre, Shiraz University of Medical Science, Shiraz, Iran.
  • Los MJ; Department Clinical & Experimental Medicine, Division of Cell Biology, and Integrative Regenerative Medical Center, Linköping University, Linköping, Sweden; Department of Pathology, Pomeranian Medical University, Szczecin, Poland. Electronic address: marek.los@liu.se.
Trends Mol Med ; 20(9): 519-28, 2014 Sep.
Article em En | MEDLINE | ID: mdl-25164066
Therapies that selectively target cancer cells for death have been the center of intense research recently. One potential therapy may involve apoptin proteins, which are able to induce apoptosis in cancer cells leaving normal cells unharmed. Apoptin was originally discovered in the Chicken anemia virus (CAV); however, human gyroviruses (HGyV) have recently been found that also harbor apoptin-like proteins. Although the cancer cell specific activity of these apoptins appears to be well conserved, the precise functions and mechanisms of action are yet to be fully elucidated. Strategies for both delivering apoptin to treat tumors and disseminating the protein inside the tumor body are now being developed, and have shown promise in preclinical animal studies.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Proteínas do Capsídeo / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Trends Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Bolívia País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sistemas de Liberação de Medicamentos / Proteínas do Capsídeo / Antineoplásicos Limite: Animals / Humans Idioma: En Revista: Trends Mol Med Assunto da revista: BIOLOGIA MOLECULAR Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Bolívia País de publicação: Reino Unido